We are pleased to share with you a recent publication in International Journal of Clinical and Experimental Medicine. This publication is entitled "Expressions and clinical significance of factors related to giant cell tumor of bone".
Please find access to the full-version of the article click here.
Li C, Zheng X, Ghert M, Li H, Wang B, Feng Y. Expressions and clinical significance of factors related to giant cell tumor of bone. Int J Clin Exp Med. 2015 Dec 15;8(12):22509-14. eCollection 2015. PubMed PMID: 26885235; PubMed Central PMCID: PMC4730021.
Giant cell tumor of bone (GCTB) is a relatively rare tumor of bone, characterized by numerous multinucleated cells, severe osteolysis, and local recurrence.
To explore the role of S-phase kinase-interacting protein 2 (Skp2), cyclin-dependent kinase inhibitor p27, and the transcription factor E2F-1 expression in the development of GCTB, and the relationship of expression of these proteins with tumor recurrence.
Forty-four patients with GCTB were selected and demographic and clinical data were collected. The levels of Skp2, p27, and E2F-1 protein expression were immunohistochemically assessed in surgical specimens.
Skp2, p27, and E2F-1 proteins were detected in the nuclei of mononuclear stromal cells. Positive Skp2 expression was observed in 66% (29/44) of GCTB patient samples, and positive p27 expression was found in 39% (17/44) of samples. Within almost all GCTB patients, there was an inverse correlation between Skp2- and p27-positive tumor cells. Positive expression of E2F-1 was present in 28 of 44 (64%) patients. In addition, expression of skp2 and p27, infiltration of soft tissues, and surgical operation were significantly associated with recurrence in patients with GCTB.
The immunohistochemical assessment of Skp2, p27 and E2F-1 may be useful in the diagnosis of GCTB and prediction of its prognosis.